Literature DB >> 12097225

Perceptual analysis of speech following traumatic brain injury in childhood.

Louise M Cahill1, Bruce E Murdoch, Deborah G Theodoros.   

Abstract

PRIMARY
OBJECTIVE: To investigate perceptually the speech dimensions, oromotor function, and speech intelligibility of a group of individuals with traumatic brain injury (TBI) acquired in childhood. RESEARCH
DESIGN: The speech of 24 children with TBI was analysed perceptually and compared with that of a group of non-neurologically impaired children matched for age and sex. MAIN OUTCOME AND
RESULTS: The 16 dysarthric TBI subjects were significantly less intelligible than the control subjects, and demonstrated significant impairment in 12 of the 33 speech dimensions rated. In addition, the eight non-dysarthric TBI subjects were significantly impaired in many areas of oromotor function on the Frenchay Dysarthria Assessment, indicating some degree of pre-clinical speech impairment.
CONCLUSION: The results of the perceptual analysis are discussed in terms of the possible underlying pathophysiological bases of the deviant speech features identified, and the need for a comprehensive instrumental assessment, to more accurately determine the level of breakdown in the speech production mechanism in children following TBI.

Entities:  

Mesh:

Year:  2002        PMID: 12097225     DOI: 10.1080/02699050110119871

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  2 in total

1.  Pediatric traumatic brain injury: language outcomes and their relationship to the arcuate fasciculus.

Authors:  Frédérique J Liégeois; Kate Mahony; Alan Connelly; Lauren Pigdon; Jacques-Donald Tournier; Angela T Morgan
Journal:  Brain Lang       Date:  2013-06-10       Impact factor: 2.381

Review 2.  Speech therapy for children with dysarthria acquired before three years of age.

Authors:  Lindsay Pennington; Naomi K Parker; Helen Kelly; Nick Miller
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.